“Transporters, Current Industry Practices, and Biologics”

Somerset Crowne Plaza Hotel
110 Davidson Avenue
Somerset, New Jersey

October 14, 2009
8:00 am – 3:30 pm


08:00 am
Registration / Continental Breakfast / Vendor Exhibit

08:50 am
Introductory Remarks
Dr. Philip Krieter, Chair, NJ-DMDG

09:00 am
The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier [slides (PDF)] Dr. Ron Borchardt, Solon E. Summerfield Distinguished Professor, Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas

09:50 am
In Vitro and In Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of American Perspective [slides (PDF)] Dr. Gondi Kumar, Senior Director, Department of Drug Metabolism and Pharmacokinetics, Celgene Corporation

10:45 am
Vendor Exhibit & Coffee Break

11:15 am
Inactivation Studies for Predicting Drug-Drug Interactions. Pharmaceutical Industry Recommendations and Recent Observations [slides (PDF)] Dr. R. Scott Obach, Senior Research Fellow, Biotransformation Group, Pharmacokinetics, Dynamics and Drug Metabolism Department, Pfizer, Inc.

12:00 Nn
Lunch & Vendor Exhibit

01:30 pm
Pharmacokinetic Based Drug-Drug Interactions of Biologicals. Science and Development Strategies [slides (PDF)] Dr. Frank-Peter Theil, Associate Director, Genentech, Inc.

02:15 pm
Vendor Exhibit & Coffee Break

02:45 pm
PK/PD Study Strategies for Biopharmaceuticals: Is Bigger Better? [slides (PDF)] Dr. Sharon A. Baughman, Biotechnology Consulting

03:30 pm
Program Closure